These findings suggest that BAFF may play a role not only in metabolism and inflammation but also in fibrosis in the pathogenesis of NASH, which indicates that it is one of the therapeutic targets in NASH. Here, TNFSF13B is linked to metabolic dysfunction-associated steatohepatitis.